• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Addiction biology >Abuse potential of intranasal buprenorphine versus buprenorphinealoxone in buprenorphine-maintained heroin users
【24h】

Abuse potential of intranasal buprenorphine versus buprenorphinealoxone in buprenorphine-maintained heroin users

机译：维持丁丙诺啡的海洛因使用者鼻内丁丙诺啡与丁丙诺啡/纳洛酮的滥用潜力

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In spite of the clinical utility of buprenorphine, parenteral abuse of this medication has been reported in several laboratory investigations and in the real world. Studies have demonstrated lower abuse liability of the buprenorphinealoxone combination relative to buprenorphine alone. However, clinical research has not yet examined the utility of the combined formulation to deter intranasal use in a buprenorphine-maintained population. Heroin-using volunteers (n=12) lived in the hospital for 8-9 weeks and were maintained on each of three sublingual buprenorphine doses (2, 8, 24mg). Under each maintenance dose, participants completed laboratory sessions during which the reinforcing and subjective effects of intranasal doses of buprenorphine (8, 16mg), buprenorphinealoxone (8/2, 8/8, 8/16, 16/4mg) and controls (placebo, heroin 100mg, naloxone 4mg) were assessed. Intranasal buprenorphine alone typically produced increases in positive subjective effects and the 8mg dose was self-administered above the level of placebo. The addition of naloxone dose dependently reduced positive subjective effects and increased aversive effects. No buprenorphinealoxone combination dose was self-administered significantly more than placebo. These data suggest that within a buprenorphine-dependent population, intranasal buprenorphinealoxone has reduced abuse potential in comparison to buprenorphine alone. These data strongly argue in favor of buprenorphinealoxone rather than buprenorphine alone as the more reasonable option for managing the risk of buprenorphine misuse. Clinical research has not examined the utility of the combined Buprenorphine/Naloxone formulation to deter intranasal abuse in a buprenorphine-maintained population. Heroin users were maintained on three sublingual buprenorphine doses (2, 8, 24 mg) while completing laboratory sessions assessing the reinforcing and subjective effects of intranasal buprenorphine (8, 16 mg), buprenorphinealoxone (8/2, 8/8, 8/16, 16/4 mg). The addition of naloxone dose-dependently reduced positive subjective effects, increased aversive and no buprenorphinealoxone dose was not self-administered.
机译：尽管丁丙诺啡具有临床用途，但在一些实验室研究和现实世界中已报告了这种药物的肠胃外滥用。研究表明，与单独使用丁丙诺啡相比，丁丙诺啡/纳洛酮组合的滥用风险较低。然而，临床研究尚未检查组合制剂在阻止丁丙诺啡维持人群中鼻内使用中的效用。使用海洛因的志愿者（n = 12）在医院生活了8-9周，并接受三种舌下丁丙诺啡剂量（2、8、24mg）的剂量。在每次维持剂量下，参与者完成了实验室会议，在此期间鼻内剂量的丁丙诺啡（8、16mg），丁丙诺啡/纳洛酮（8 / 2、8 / 8、8 / 16、16 / 4mg）和对照的加强和主观作用（评估安慰剂，海洛因100mg，纳洛酮4mg）。单独的鼻内丁丙诺啡通常会产生积极的主观效果，并且在安慰剂水平以上自行服用8mg剂量。纳洛酮剂量的增加会相应地降低阳性主观效果并增加厌恶效果。丁丙诺啡/纳洛酮联合用药的自我剂量没有明显高于安慰剂。这些数据表明在丁丙诺啡依赖性人群中，与单独使用丁丙诺啡相比，鼻内丁丙诺啡/纳洛酮的滥用潜力有所降低。这些数据强烈支持丁丙诺啡/纳洛酮，而不是单独使用丁丙诺啡作为管理丁丙诺啡滥用风险的更合理选择。临床研究尚未检查丁丙诺啡/纳洛酮联合制剂在阻止丁丙诺啡维持的人群鼻内滥用中的作用。海洛因使用者维持三种舌下丁丙诺啡剂量（2、8、24 mg），同时完成实验室评估鼻内丁丙诺啡（8、16 mg），丁丙诺啡/纳洛酮（8 / 2、8 / 8、8）的增强和主观作用/ 16，16/4 mg）。纳洛酮的剂量依赖性地降低了阳性主观效果，增加了厌恶感，并且没有自行服用丁丙诺啡/纳洛酮剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号